The use of electrical stimulation of nerves or brain centres as a therapeutic tool is being trialled in an increasing range of human diseases, including Parkinson disease, arthritis, depressive illness, schizophrenia, pain and bladder dysfunction. This treatment approach is referred to variously as, simply, neuromodulation, or as bioelectric neuromodulation or electroceuticals. The possibility that bioelectric neuromodulation could be used to relieve gastrointestinal-related disorders has created considerable interest in the clinical community, and stimulation at a range of sites of the gastrointestinal tract for several different conditions has been investigated.
In most cases, outcomes have been variable and mechanisms of action remain unclear, leaving important therapeutic questions unanswered, for example, optimal stimulus parameters, which have been reviewed elsewhere. Possible target populations and strategies for neuromodulation therapies applied to the gut have also been reviewed. A clear understanding of the biology of the innervation of the gastrointestinal tract is therefore needed to maximize the effectiveness and minimize the adverse effects of bioelectrical neuromodulation therapy.
Fig. 1 Sites of bioelectric neuromodulation to change gastrointestinal functions. (Payne SC, et al., 2019)
Crohn's disease and ulcerative colitis, collectively termed IBD, are the most common immune-mediated disorders of the gastrointestinal tract. In a substantial proportion of these patients the disease recurs despite ongoing biological or pharmacological preventive treatment. Thus, new therapies that are more effective and have fewer adverse effects than current treatments are needed.
VNS for IBD. Experimental and clinical trials of vagal nerve stimulation (VNS) to alleviate IBD have had variable outcomes. VNS (3 hours per day) applied to awake rats with TNBS-induced colitis effectively reduced weight loss, colonic histological score and molecular expression of pro-inflammatory cytokines that were measured in the intestine adjacent to the inflammatory lesion.
SNS for IBD. In a single patient with proctitis, sacral nerve stimulation (SNS) to relieve faecal incontinence improved the state of the rectal mucosa.
Obesity treatment is among the most developed applications for bioelectric neuromodulation. Neuromodulation devices for the treatment of obesity have been used to change activity in the vagus nerve directly or have been applied to the gastric surface.
Vagal nerve blocking for obesity. Cutting the abdominal vagus causes a decrease in food intake in individuals with healthy weight and those with obesity, and in laboratory rats.
VNS for obesity. VNS might have an additional benefit in individuals with obesity, as obesity results in chronic low-grade inflammation that is involved in the pathogenesis of obesity-related insulin resistance and type 2 diabetes mellitus.
GES for obesity. Gastric electrical stimulation (GES) is a term used to describe electrical stimulation to the surface of the stomach or to vagal branches on the gastric surface.
Faecal continence and defecation are under voluntary control in humans, who can, in healthy conditions, decide when to retain or release bowel contents. However, the control is impaired in patients with disorders, including Parkinson disease, multiple sclerosis, childhood constipation and idiopathic conditions, that are associated with diarrhoea, faecal soiling or constipation. In the search for better treatments for colorectal disorders, a range of bioelectric neuromodulation methods have been investigated.
SNS for faecal incontinence. Pelvic nerve stimulation, generally referred to as sacral nerve stimulation (SNS) because the autonomic outflows (pelvic nerves) from the lower spinal cord run initially in the sacral nerves, has been used for >20 years to treat faecal incontinence.
SARS for constipation. Sacral anterior root stimulation (SARS) is a modification of SNS for treating constipation. In a study in >200 patients with constipation as a consequence of SCI (median age 49 years), SARS increased the frequency of defecation, reduced bowel emptying times and reduced the use of oral laxatives or suppositories and digital evacuation compared with patients pre-implant.
TIENS for constipation. Transcutaneous interferential electrical nerve stimulation (TIENS) is a method in which oscillating currents, generally 1-4 kHz sinusoidal currents, are passed between pairs of surface electrodes.
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | Inquiry |
| ADV | DEIAFY103 | Adenovirus Hexon Antigen ELISA Kit | 2×96T | N/A | Qualitative | Feces | Inquiry |
| ADV | DEIASL108 | Mouse Adenovirus FL ELISA Kit | 96T | Mouse | Qualitive | Serum | Inquiry |
| ADV | DEIASL109 | Mouse Adenovirus K87 ELISA Kit | 96T | Mouse | Qualitive | Serum | Inquiry |
| ADV | DEIA309 | Human Anti-Adenovirus IgG ELISA Kit | 96T | Human | Quantitative | Serum, plasma | Inquiry |
| ADV | DEIA310 | Adenovirus IgA ELISA Kit | 96T | Human | Quantitative | serum, plasma | Inquiry |
| ADV | DEIA311 | Adenovirus IgM ELISA Kit | 96T | Human | Quantitative | serum, plasma | Inquiry |
| ADV | DEIA1767 | Adenovirus IgM ELISA Kit | 96T | Human | Semi-Quantitative, Qualitative | serum | Inquiry |
| ADV | DEIA2435 | Adenovirus (Fecal) ELISA Kit | 96T | N/A | Qualitative | Stool | Inquiry |
| ADV | DEIA2382 | Adenovirus IgG ELISA Kit | 96T | Human | Qualitative | Human serum or plasma (citrate, heparin) | Inquiry |
| ADV | DEIA2094 | Mouse Adenovirus-FLandK87 EcoELISA Kit | 96T | Mouse | Qualitative | serum | Inquiry |
| ADV | DEIA1383 | Human Adenovirus IgA (ADV-IgA) ELISA Kit | 96T | Human | Qualitative | Serum or plasma | Inquiry |
| ADV | DEIA1383G | Human Adenovirus IgG ELISA Kit | 96T | Human | Qualitative | Serum, plasma | Inquiry |
| C. Jejuni | DEIA-XY89 | Campylobacter jejuni IgA ELISA Kit | 96T | Human | Quantitative | serum, EDTA plasma, heparin plasma, citrate plasma | Inquiry |
| C. Jejuni | DEIA-XY90 | Campylobacter jejuni IgG ELISA Kit | 96T | Human | Qualitative | Serum or plasma (EDTA, citrate, heparin). | Inquiry |
| C. Jejuni | DEIA-XY91 | Campylobacter jejuni IgM ELISA Kit | 96T | Human | Quantitative | serum, EDTA plasma, heparin plasma, citrate plasma | Inquiry |
| Calprotectin | DEIA2176F | Mouse/Rat S100A8/S100A9 ELISA Kit | 96T | Mouse, Rat | Quantitative | stool, serum, plasma, urine, tissue extract, cell culture supernatant | Inquiry |
| Calprotectin | DEIABL65 | Human S100A8/S100A9 Heterodimer ELISA development kit | 96T×5 | Human | Quantitative | Cell culture supernate, serum, plasma, saliva, human milk, urine, and fecal samples | Inquiry |
| Calprotectin | DEIABL64 | Mouse S100A8/S100A9 Heterodimer ELISA development kit | 96T×5 | Mouse | Quantitative | Cell culture supernate, serum, and plasma samples | Inquiry |
| Calprotectin | DEIA-XY2170 | Mouse S100A9/Calprotectin ELISA kit | 96T | Mouse, Goat, Pig, Rabbit | Quantitative | serum, plasma | Inquiry |
| Calprotectin | DEIA52610PY | Chicken Calprotectin ELISA Kit | 96T | Chicken | Quantitative | Serum, plasma, tissue homogenates and other biological fluids. | Inquiry |
| Calprotectin | DEIA042J | Calprotectin (MRP 8/14) ELISA Kit | 96T | Human | Quantitative | stool | Inquiry |
| Calprotectin | DEIA043J | Calprotectin (MRP 8/14) ELISA Kit | 96T | Human | Quantitative | urine | Inquiry |
| Calprotectin | DEIA2223 | Human Calprotectin Stool ELISA Kit | 96T | Human | Quantitative | stool | Inquiry |
| Calprotectin | DEIA2166 | Human Calprotectin ELISA | 96T | Human | Quantitative | Stool, Serum, Urine, Sputum, Plasma | Inquiry |
| Calprotectin | DAEF-012 | Pig calprotectin (CALP) ELISA Kit | 96T | Quantitive | Serum, Plasma and Tissue Homogenates | Inquiry | |
| Calprotectin | DEIA2166R | Human S100A8/S100A9 Heterodimer ELISA Kit | 96T | Human | Quantitative | Cell culture supernates, tissue lysates, serum, plasma, saliva, urine, human milk, fecal extract | Inquiry |
| Crypto | DEIA2436 | Cryptosporidium (Fecal) ELISA Kit | 96T | Human | Qualitative | feces | Inquiry |
| H. pylori | DEIA341 | Human Helicobacter pylori IgG ELISA kit | 96T | Human | Quantitative | serum, plasma | Inquiry |
| H. pylori | DEIA342 | Human Helicobacter pylori IgA ELISA kit | 96T | Human | Quantitative | serum, plasma | Inquiry |
| H. pylori | DEIA343 | Human Helicobacter pylori IgM ELISA kit | 96T | Human | Quantitative | serum, plasma | Inquiry |
| H. pylori | DEIA-BJ763 | Human Helicobacter pylori-Hsp60 ELISA kit | 96T | Human | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry |
| H. pylori CagA | DEIA1900 | CagA IgG ELISA Kit | 96T | Human | Qualitative | serum, plasma | Inquiry |
| H. pylori | DEIA1951 | H. Pylori Ag Stool Extraction Kit | 50T | Inquiry | |||
| H. pylori | DEIABL338 | Helicobacter pylori-Antigen ELISA Kit | 96T | N/A | Quantitative, Qualitative | feces | Inquiry |
| H. pylori | DEIA1865 | H. Pylori Antibody IgA ELISA Kit | 96T | Human | Qualitative | serum, plasma, stool | Inquiry |
| H. pylori | DEIA1780 | Helicobacter pylori IgA ELISA Kit | 96T | Human | Qualitative | serum | Inquiry |
| H. Pylori | DEIACL36 | CDSimple™ Anti-H. Pylori IgA Chemiluminescent ELISA Kit | 96T | Human | Quantitative | Serum | Inquiry |
| H. Pylori | DEIACL37 | CDSimple™ Anti-H. Pylori IgG Chemiluminescent ELISA Kit | 96T | Human | Quantitative | Serum | Inquiry |
| H. Pylori | DEIACL38 | CDSimple™ Anti-H. Pylori IgM Chemiluminescent ELISA Kit | 96T | Human | Quantitative | Serum | Inquiry |
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | Inquiry |
| Calprotectin | DTS599 | Calprotectin Rapid Test | 20T | Human | Qualitative | Faeces | Inquiry |